OTHER RECEIVABLES Financial Updates

PT INDOFARMA PERSERO TBK PT INDOFARMA PERSERO TBK DAN ENTITAS ANAK AND SUBSIDIARY CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO CONSOLIDATED FINANCIAL STATETMENTS 31 Desember 2013 dan 2012 December 31, 2013 and, 2012 Untuk Tahun-tahun Yang Berakhir 31 Desember 2013 dan 2012 For the Years Ended December 31, 2013 and 2012 Dinyatakan dalam Rupiah Expressed in Full Rupiah 18. PINJAMAN BANK 18. BANK BORROWINGS PT Bank Mandiri Persero Tbk: PT Bank Mandiri Persero Tbk - Entitas Induk Parent Company - - Entitas Anak Subsidiary - Jumlah bersih Total - Net a. PT Bank Mandiri Persero Tbk Entitas Induk a. PT Bank Mandiri Persero Tbk - Parent Company b. PT Bank Mandiri Persero Tbk Entitas Anak b. PT Bank Mandiri Persero Tbk - Subsidiary 51.580.353.536 24.374.999.999 Company obtained working capital loan based on Letter from Bank Mandiri No. CBG.CB2SPPK.D02.0052013 dated June 12,2013 after several times changes of loan agreement. Credit limit according to the letter is amounted Rp150,000,000,000 with interest rate 9.25 and loan maturity date June 21, 2014. Besides, the Company also have Foreign Exchange Line Facility amounted USD5,000,000 Open LC Facility or SKBDN local LCamounted USD7,500,000 and Bank Guarantee amounted Rp5,000,000,000. Colateral pledged by the Company are inventories, receivables, land, building, plant, machine and office supplies in Cibitung.The terms of financial covenant that have to be fullfiled by the Company include Current Ratio minimum 120, Debt to Equity Ratio maximum 150 and Debt Service Coverage minimum 100. 199.154.049.563 174.987.382.896 PT Indofarma Global Medika IGM - entitas anak memperoleh fasilitas kredit modal kerja transaksional dari PT Bank Mandiri Persero Tbk, berdasarkan surat dari Bank Mandiri No. CBG.CB2SPPK.D02.0072013 tanggal 12 Juni 2013 dengan nilai fasilitas kredit sebesar Rp200.000.000.000 yang terdiri dari KMK Rekening Koran sebesar Rp30.000.000.000 dan KMK Non Rekening Koran sebesar Rp170.000.000.000 tingkat bunga 9,25 per tahun dan jatuh tempo tanggal 21 Juni 2014. Pinjaman tersebut dijamin dengan persediaan dan piutang dagang yang diikat fidusia, Jaminan Tidak Bergerak terkait dengan jaminan aset tetap a.n induk Perseroan PT Indofarma Persero Tbk, dan Corporate Guarantee dari PT Indofarma Persero Tbk. Selain itu Perseroan harus memenuhi financial covenant Current Ratio minimal 110, Debt to Equity Ratio maksimal sebesar 425 dan Debt Service Coverage minimal sebesar 200. Akun ini merupakan Kredit Modal Kerja dari Bank Mandiri dengan rincian sebagai berikut: 31 Desember 2013 December 31, 2013 75.955.353.535 The Subsidiary obtained credit facilities transactional working capital. Bank Mandiri Persero Tbk, according to a letter from PT Bank Mandiri No. CBG.CB2SPPK.D02.0072013 June 12, 2013 with the value of credit facilities amounting to Rp200,000,000,000 consist of account working capital credit amounted to Rp30,000,000,000 and Non account working capital credit amounted to Rp170,000,000,000 with interest rate of 9.25 per annum and maturing June 21, 2013. The loan is secured by the stock and trade receivables are tied fiduciary, Warranty Not Move associated with fixed asset guarantees the parent company, PT Indofarma Persero Tbk, and Corporate Guarantee of PT Indofarma Persero Tbk. In addition, the Company must comply with financial covenants at least 110 Current Ratio Debt to Equity Ratio of 425 maximum and minimum Debt Service Coverage of 200. 24.166.666.667 31 Desember 2012 December 31, 2012 This account is a Working Capital Loan from Bank Mandiri with the following details: Perseroan memperoleh Kredit Investasi dari Bank Mandiri sesuai surat No.CBG.CB2SPPK.D02.072012 tanggal 15 Juni 2012 dengan realisasi pencairan sebesar Rp8.676.581.799 dengan plafon sebesar Rp67.000.000.000 enam puluh tujuh milyar rupiah dengan suku bunga 9,25 pertahun dengan Jangka waktu 5,5 tahun, kredit Investasi tersebut digunakan untuk renovasi produksi herbal, produksi steril, renovasi dan pembangunan fasilitas pilot plan serta pembangunan fasilitas produksi FDC. Catatan 23 The Company obtained investment credit line from Bank Mandiri No.CBG.CB2SPPK.D02.072012 letter dated June 15, 2012 with first disbursment amounted to Rp8,676,581,799 of a ceiling of Rp67,000,000,000 sixty seven billion rupiah with 9,25 interest per annum with a term of 5,5 years, investment credits are used for renovation production facilities of herbal, sterile, renovation and costruction of pilot plan facilities, and construction FDC production facilities.Notes 23 Entitas Induk mendapatkan kredit modal kerja dari Bank Mandiri dan perjanjian kredit telah mengalami beberapa kali perubahan dengan perubahan terakhir berdasarkan surat dari Bank Mandiri No. CBG.CB2SPPK.D02.0052013 tanggal 12 Juni 2013 dengan tingkat suku bunga 9,25 sewaktu waktu dapat berubah sesuai ketentuan yang berlaku di PT Bank Mandiri dan jatuh tempo tanggal 21 Juni 2014. Plafon pinjaman berdasarkan surat tersebut sebesar Rp150.000.000.000, Fasilitas Foreign Exchange Line USD 5.000.000, Fasilitas pembukaan LC Impor atau SKBDN sebesar USD7.500.000 dan bank garansi khusus untuk jaminan pembayaran kepada supplier Rp5.000.000.000. Jaminan berupa sediaan, piutang dagang, tanah, bangunan pabrik, mesinperalatan pabrik dan inventaris kantorpabrik di Cibitung. Selain itu Perseroan harus memenuhi financial covenant Current Ratio minimal 120, Debt to Equity Ratio maksimal sebesar 150, dan Debt Service Coverage Ratio minimal sebesar 100 . Halaman 40 Page PT INDOFARMA PERSERO TBK PT INDOFARMA PERSERO TBK DAN ENTITAS ANAK AND SUBSIDIARY CATATAN ATAS LAPORAN KEUANGAN KONSOLIDASIAN NOTES TO CONSOLIDATED FINANCIAL STATETMENTS 31 Desember 2013 dan 2012 December 31, 2013 and, 2012 Untuk Tahun-tahun Yang Berakhir 31 Desember 2013 dan 2012 For the Years Ended December 31, 2013 and 2012 Dinyatakan dalam Rupiah Expressed in Full Rupiah 19. UTANG USAHA 19. TRADE PAYABLES Pihak-pihak Berelasi Related Parties PT RNI Persero PT RNI Persero PT Kimia Farma Persero Tbk PT Kimia Farma Persero Tbk PT Bio Farma PT Bio Farma Subjumlah Pihak Berelasi a Subtotal Related Parties a Pihak Ketiga Third Parties PT Airindo PT Airindo PT Merapi Utama Pharma PT Merapi Utama Pharma PT. Petan Daya Medica PT. Petan Daya Medica PT Tigaka Distrindo PT Tigaka Distrindo PT Afi Farma PT Afi Farma PT Global Chemindo M PT Global Chemindo M PT Lucas Jaya PT Schot Igar Glass PT Schot Igar Glass PT Schot Igar Glass Satya Samita Niagatama Satya Samita Niagatama PT Satya Abadi Pharma PT Satya Abadi Pharma PT. Citra Jananuraga Hutama PT. Citra Jananuraga Hutama PT Menjangan Sakti PT Menjangan Sakti PT. B. Braun PT. B. Braun PT Avesta Continental Pack PT Avesta Continental Pack PT Maxiair Indosurya PT Maxiair Indosurya PT. Surgika Alkesindo PT Avesta Continental PT Tatarasa Primatama PT Indokonverta Indah PT Rama Emerald Multi PT Rama Emerald Multi PT Bernofarm PT Bernofarm Anindojaya Swakarsa Anindojaya Swakarsa Sri Aman Corporation KOPAMA PT Erela PT Erela PT Anugerah Pharmindo Lestari PT Anugerah Pharmindo Lestari PT. Advance Medicare Corpora PT. Advance Medicare Corpora PT Fokus Diagnostic Indonesia PT Fokus Diagnostic Indonesia PT Capsugel Indonesia PT Capsugel Indonesia PT. Yasatama Paramitra PT. Yasatama Paramitra PT. Evanusa PT. Evanusa PT Kairos Tritunggal PT Kairos Tritunggal PT Holi Pharma PT Holi Pharma KSEI KSEI PT Signa Husada PT Signa Husada CV. Puspa Sari CV. Puspa Sari PT. Dian Graha Elektrika PT. Dian Graha Elektrika PT Indokonverta Indah PT Indokonverta Indah PT Mulya Husada Jaya PT Mulya Husada Jaya PT. Setio Harto PT. Setio Harto PT Enseval PT Enseval PT. IDS Medical System Indonesia PT. IDS Medical System Indonesia PT Novapharin PT Novapharin PT Dos Ni Roha PT Dos Ni Roha PT. Sigma Andalan Nusa PT. Sigma Andalan Nusa KANTOR PELAYANAN PAJAK PND KANTOR PELAYANAN PAJAK PND Mutiara Mutiara KOPAMA KOPAMA PT Merial Esa PT Merial Esa PT Unijaya Pratama PT Sinar Tosan Mandiri PT. Promed Rahardjo Farmasi Indonesia PT. Promed Rahardjo Farmasi Indonesia PT Mega Medika Mandiri PT Mega Medika Mandiri PT. Trimitra Pratama Mulia Mandiri PT. Trimitra Pratama Mulia Mandiri Subjumlah Dipindahkan Next Subtotal 6.883.521.301 4.192.371.118 - 14.518.616.760 - 8.953.840.641 15.459.454.300 20.174.130.581 18.657.516.268 - 8.239.527.752 3.610.931.080 - - - - 3.348.611.923 2.934.099.223 1.578.983.200 6.062.210.548 22.491.603.527 3.572.094.065 2.756.424.270 2.718.766.824 - 4.120.914.500 2.790.013.015 38.104.177.134 31 Desember 2012 December 31, 2012 1.064.944.749 4.351.499.498 - 3.566.704.724 - 3.404.824.842 11.182.472.081 39.887.787.486 335.257.790 2.253.230.059 1.194.414.589 2.618.421.436 - - 1.945.091.613 1.532.519.338 - 4.111.172.727 - 1.660.300.410 1.729.665.000 Utang usaha terutama merupakan utang atas pembelian produk jadi, bahan baku dan suku cadang dari pemasok sebagai berikut: 31 Desember 2013 December 31, 2013 901.530.383 1.519.636.097 This account represents payable arising from purchase of medicine, raw material and spare parts from vendor with detail as follows: - 1.329.005.422 1.676.929.432 - 2.422.029.999 2.775.000.000 - 1.557.257.192 1.561.390.073 2.235.004.083 2.153.728.866 2.226.400.454 - 1.645.003.091 4.609.460.000 4.227.272.727 25.079.905.169 2.981.818.427 3.794.012.629 3.692.415.500 1.007.218.334 - 4.067.487.709 4.066.003.809 3.284.516.192 2.618.652.340 2.295.507.006 - 5.186.225.693 2.310.525.827 - - - 7.900.269.320 - - - 2.124.368.107 9.167.129.363 1.738.215.715 1.315.016.132 - - 3.450.583.254 1.622.224.061 2.260.515.080 1.322.522.304 - 63.498.146.940 314.064.637 - 2.963.559.214 2.274.092.270 - 4.068.212.010 2.802.949.404 3.092.025.239 257.957.634.335 82.677.167.120 Halaman 41 Page